Skip to main content
Erschienen in: Rheumatology International 10/2010

01.08.2010 | Original Article

The −283C/T polymorphism of the DNMT3B gene influences the progression of joint destruction in rheumatoid arthritis

verfasst von: Eon Jeong Nam, Kyung Hoon Kim, Seung Woo Han, Chang Min Cho, Jongmin Lee, Jae Yong Park, Young Mo Kang

Erschienen in: Rheumatology International | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study is to investigate the association between the −283C/T polymorphism at the promotor of DNMT3B gene and susceptibility to rheumatoid arthritis (RA) and to evaluate the effect of the polymorphism on clinical features such as progression of joint destruction in RA. A total of 309 patients with RA were compared with 297 control subjects. Genotyping of the −283C/T polymorphism was performed by real-time sequencing using Pyrosequencer. The genotype frequencies of the polymorphism at position −283 were not significantly different between patients with RA and controls. There were significantly positive correlations between the modified Sharp score and the disease duration for carriers of each genotype (y = 9.546x + 19.998, p < 0.001, for T allele carriers, y = 6.185x + 34.424, p < 0.001 for CC homozygotes). The slope of regression line of the T allele carriers was significantly steeper than that of the CC homozygotes (p = 0.014). In conclusion, our results suggest that the −283C/T polymorphism of the DNMT3B gene is a genetic marker related to the joint destruction of RA.
Literatur
5.
Zurück zum Zitat Quddus J, Johnson KJ, Gavalchin J et al (1993) Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92:38–53. doi:10.1172/JCI116576 CrossRefPubMed Quddus J, Johnson KJ, Gavalchin J et al (1993) Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92:38–53. doi:10.​1172/​JCI116576 CrossRefPubMed
6.
Zurück zum Zitat Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M (1990) Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665–1673. doi:10.1002/art.1780331109 CrossRefPubMed Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M (1990) Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665–1673. doi:10.​1002/​art.​1780331109 CrossRefPubMed
9.
Zurück zum Zitat Okano M, Xie S, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19:219–220. doi:10.1038/890 CrossRefPubMed Okano M, Xie S, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19:219–220. doi:10.​1038/​890 CrossRefPubMed
11.
Zurück zum Zitat Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C → T promoter polymorphism and risk of breast cancer in a British population: a case–control study. Breast Cancer Res 6:R390–R394. doi:10.1186/bcr807 CrossRefPubMed Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C → T promoter polymorphism and risk of breast cancer in a British population: a case–control study. Breast Cancer Res 6:R390–R394. doi:10.​1186/​bcr807 CrossRefPubMed
12.
15.
Zurück zum Zitat Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC (1995) Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025–3035PubMed Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC (1995) Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025–3035PubMed
16.
Zurück zum Zitat Bruniquel D, Schwartz RH (2003) Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 4:235–240. doi:10.1038/ni887 CrossRefPubMed Bruniquel D, Schwartz RH (2003) Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 4:235–240. doi:10.​1038/​ni887 CrossRefPubMed
17.
Zurück zum Zitat Mikovits JA, Young HA, Vertino P et al (1998) Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol 18:5166–5177PubMed Mikovits JA, Young HA, Vertino P et al (1998) Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol 18:5166–5177PubMed
18.
Zurück zum Zitat Richardson BC (2002) Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 132:2401S–2405SPubMed Richardson BC (2002) Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 132:2401S–2405SPubMed
Metadaten
Titel
The −283C/T polymorphism of the DNMT3B gene influences the progression of joint destruction in rheumatoid arthritis
verfasst von
Eon Jeong Nam
Kyung Hoon Kim
Seung Woo Han
Chang Min Cho
Jongmin Lee
Jae Yong Park
Young Mo Kang
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 10/2010
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1141-y

Weitere Artikel der Ausgabe 10/2010

Rheumatology International 10/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.